While direct evidence examining the impact of insulin-sensitizing medications (such as metformin, GLP-1 agonists, or SGLT2 inhibitors) on the progression of chILD is currently lacking, insights can be gleaned from related conditions. Here, INS is linked to interstitial lung disease specific to childhood.